ÄRZTE – Dr. Frank Kanniess

Allergologie, Lungenerkrankungen, Schlaferkrankungen, Diabetes Mellitus

Dr. Frank Kanniess
f.kanniess@gpr-reinfeld.de

Dr. Kanniess war von 1995 bis 2007 im Krankenhaus Großhansdorf (Zentrum für Pneumologie und Thoraxchirirgie) und dem Pneumologischen Forschungsinstitut am Krankenhaus Großhansdorf tätig. Daher liegt ein Arbeitsschwerpunkt in der Diagnostik und Behandlung von allergischen Atemwegserkrankungen und der COPD (Raucherlunge) sowie von schlafbezogenen Atmungsstörungen.

Facharzt für Allergologie, Fachzertifikat Diabetologie, Schulungszertifikat MEDIAS (Diabetes mellitus), NASA (Asthma bronchiale), COBRA (COPD).

Neben der Praxistätigkeit Berater verschiedener pharmazeutischer Unternehmen (Zulassungsberatung, Vorträge, Advisory Boards), sowie Schulungstätigkeit für Haus- und Fachärzte. Weiterhin wissenschaftliche Tätigkeit im Bereich der Atemwegserkrankungen (Asthma, COPD).

Hausärztlich tätig in der Gemeinschaftspraxis Reinfeld seit 2007.

Publikationen Dr. Frank Kanniess

  1. Efficacy of Disease Management Programs Asthma and COPD? Results of a Cross-Sectional Study
    Kanniess F, Krockenberger K, Oepen P, Hedrich R, Olbrich D, Hessler N, Ziegler A, Langer-Brauburger B.
    Dtsch Med Wochenschr. 2018 Nov 14. doi: 10.1055/a-0672-2461.
  2. Patient Satisfaction and Clinical Outcomes with Budesonide plus Formoterol Spiromax for Asthma and Chronic Obstructive Pulmonary Disease: A Real-World, Observational Trial.
    Gillissen A, Gessner C, Hechenbichler K, Herth FJF, Juenemann R, Kanniess F, Kardos P, Lommatzsch M, Schneidereit R, Windisch W. Respiration. 2018 Nov 2:1-10. doi: 10.1159/000493860
  1. Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler - Results from a non-interventional study.
    Schmidt O, Petro W, Hoheisel G, Kanniess F, Oepen P, Langer-Brauburger B.
    Respir Med. 2017 Oct;131:166-174. doi: 10.1016/j.rmed.2017.08.017
  2. Papiertiger oder Patientennutzen? DMP Asthma und COPD Kanniess F. Kongress Dt Ges Pneumologie 2017;
    GERman Dmp-Asthma (GERDA) / GERmaN cOpd Dmp (GERNOD): Effekte der Disease Management Programme Asthma bronchiale und COPD; Kanniess F. Kongress der Dt Ges Allgemeinmedizin 2017
  1. Kanniess F, Kanniess F, Diamant Z, Lomax M. Effects of low- versus high-dose fluticasone propionate/formoterol fumarate combination therapy on AMP challenge in asthmatic patients: A double-blind, randomised clinical trial. Pulm Pharmacol Ther. 2016;37:65-72
  2. Bostantzoglou C, Delimpoura V, Samitas K, Zervas E, Kanniess F, Gaga M. Clinical asthma phenotypes in the real world: opportunities and challenges. Breathe. 2015;11:186-93
  3. Ostrem A, Williams S, Pinnock H; International Primary Care Respiratory Group. We must join forces in the battle against COPD.
    Eur Respir J. 2015;46:1526-8
  4. James AJ, Reinius LE, Verhoek M, Gomes A, Kupczyk M, Hammar U, Ono J, Ohta S, Izuhara K, Bel E, Kere J, Söderhäll C, Dahlén B, Boot RG, Dahlén SE; BIOAIR (Longitudinal Assessment of Clinical Course and Biomarkers in Severe Chronic Airway Disease) Consortium. Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016;193:131-42
  1. Bardin P, Kanniess F, Gauvreau G, Bredenbröker D, Rabe KF. Roflumilast for asthma: Efficacy findings in mechanism of action studies. Pulm Pharmacol Ther. 2015 Aug 18. pii: S1094-5539(15)00091-7. doi: 10.1016/j.pupt.2015.08.006.
  2. Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;191(9):1001-11
  3. Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S. Extrafine beclomethasone/ formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial. Pulm Pharmacol Ther. 2015;30:121-7
  1. Kupczyk M, Dahlén B, Sterk PJ, Nizankowska-Mogilnicka E, Papi A, Bel EH, Chanez P, Howarth PH, Holgate ST, Brusselle G, Siafakas NM, Gjomarkaj M, Dahlén SE; BIOAIR investigators. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy. 2014;69:1198-204
  2. Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, Nizankowska-Mogilnicka E, Gjomarkaj M, Gaga M, Brusselle G, Dahlén B, Dahlén SE; BIOAIR investigators. Frequent exacerbators--a distinct phenotype of severe asthma. Clin Exp Allergy. 2014;44:212-21
  3. Pedersen F, Holz O, Kanniess F, Zielen S, Schulze J, Gillissen A, von Berg A, Berdel D, Beier J, Beeh K, Schnoor M, Magnussen H. Longitudinal measurement of airway inflammation over one year in children and adults with intermittent asthma. BMC Res Notes. 2014;7:925
  1. Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner WA. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol. 2013;131:866-74
  2. Reinius LE, Gref A, Sääf A, Acevedo N, Joerink M, Kupczyk M, D'Amato M, Bergström A, Melén E, Scheynius A, Dahlén SE; BIOAIR Study Group, Pershagen G, Söderhäll C, Kere J. DNA methylation in the Neuropeptide S Receptor 1 (NPSR1) promoter in relation to asthma and environmental factors. PLoS One. 2013;8(1):e53877. doi: 10.1371/journal.pone.0053877. Epub 2013 Jan 23.
  3. Kupczyk M, Haque S, Sterk PJ, Nizankowska-Mogilnicka E, Papi A, Bel EH, Chanez P, Dahlén B, Gaga M, Gjomarkaj M, Howarth PH, Johnston SL, Joos GF, Kanniess F, Tzortzaki E, James A, Middelveld RJ, Dahlén SE; on behalf of the BIOAIR investigators. Detection of exacerbations in asthma based on electronic diary data: results from the 1-year prospective BIOAIR study. Thorax.2013;68:611-8
  4. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369:1491-501
  1. Ritz T, Kullowatz A, Goldman MD, Kanniess F, Magnussen H, Dahme B. Emotional reactivity of the airways in asthma: Consistency across emotion-induction techniques and emotional qualities. Biol Psychol. 2010 Mar 6. [Epub ahead of print]
  2. Ritz T, Kullowatz A, Goldman MD, Smith HJ, Kanniess F, Dahme B, Magnussen H. Airway response to emotional stimuli in asthma: the role of the cholinergic pathway. J Appl Physiol. 2010;108:1542-9.
  3. Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010; 104:865-873
  4. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64:1619-31
  1. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549-58.
  2. van den Berge M, Arshad SH, Ind PW, Magnussen H, Hamelmann E, Kanniess F, Postma DS. Similar efficacy of ciclesonide versus prednisolone to treat asthma worsening after steroid tapering. Respir Med. 2009 Mar 17.
  1. Kullowatz A, Rosenfield D, Dahme B, Magnussen H, Kanniess F, Ritz T. Stress effects on lung function in asthma are mediated by changes in airway inflammation. Psychosom Med 2008; 70: 468 - 475
  2. Ritz T, Kullowatz A, Kanniess F, Dahme B, Magnussen H. Perceived triggers of asthma: evaluation of a German version of the Asthma Trigger Inventory Respir Med. 2008;102:390 - 398
  3. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, Drent M; Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31:1189-96.
  4. Ritz T, Kullowatz, A, Bobb C, Dahme B, Magnussen H, Kanniess F, Streptoe A. Psychological triggers and hyperventilation symptoms in asthma. Ann Allergy Asthma Immunol. 2008;100:426-32
  5. Kanniess F, Boulet LP, Pierzchala W, Cameron R, Owen R, Higgins M Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study. J Asthma 2008;45:887-92
  1. Kullowatz A, Kanniess F, Dahme B, Magnussen H, Ritz T. Association of depression and anxiety with health care use and quality of life in asthma patients. Respir Med. 2007;101:638-44.
  2. von Leupoldt A, Kanniess F, Dahme B. The influence of corticosteroids on the perception of dyspnea in asthma. Respir Med. 2007;101:1079-87
  3. Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007;29:871-8
  4. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother. 2007;56:1637-44
  5. Watz H, Kanniess F, Magnussen H. New pharmacological options in the therapy of COPD. Pneumologie 2007;61:365-73
  1. Watz H, Bitter-Suermann S, Kanniess F, Magnussen H COPD - pharmakologische Basisbehandlung und Zukunft der antiinflammatorischen Therapie. Med Klin 2006; 101:283-92
  1. Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, Vessey RS, Janicki S, Magnussen H, Jorres RA, Richter K. Validation of the Human Ozone Challenge Model as a Tool for Assessing Anti-Inflammatory Drugs in Early Development. J Clin Pharmacol. 2005;45:498-503
  2. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45:146-52
  3. Kanniess F, Joerres RA, Magnussen H. Effect of reproterol either alone or combined with disodium cromoglycate on airway responsiveness to methacholine Pulm Pharmacol Ther 2005;18:315-20
  4. Kanniess F, Schlitt C, Joerres RA, Magnussen H. Effect of Oxitropium, Salbutamol and their combination on hypertonic saline induced airway obstruction in COPD. Respir Medicine 2005
  5. Ludwig-Sengpiel A, Jaksztat E, Welker L, Kanniess F, Jörres RA, Magnussen H, Kirsten D. Effect of beclomethasone diproprionate (BDP) as a extrafine aerosol on bronchoalveolar lavage (BAL) lymphocytes in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:214-21
  6. Gaga M, Papageorgiou N, Yiourgioti G, Karydi P, Liapikou A, Bitsakou H, Zervas E, Koulouris NG, Holgate ST; on behalf of the ENFUMOSA study group Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire Clin Exp Allergy. 2005; 35:954-9
  1. Holz O, Zuhlke I, Einhaus M, Welker L, Kanniess F, Branscheid D, Nakashima M, Harrison LI, Jörres RA, Richter K, Magnussen H. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulm Pharmacol Ther. 2004;17 : 233-8.
  2. Kanniess F, Beier J, Kleine-Tebbe J, Magnussen H. Effect of inhaled EPI-12323 on allergen response in allergic asthmatics. Am J Respir Crit Care Med 2004; 7: A322
  3. Kanniess F, Beier J, Janicki S, Richter K, Beeh KM, Buhl R, Magnussen H. Effect of two single doses of the oral Beta-1 Integrin-Antagonist SB683698 vs inhaled fluticasone propionate on allergen-induced bronchoconstriction in mild asthma. Am J Respir Crit Care Med 2004; 169: A 323
  4. Kanniess F, Boehme S, Joerres RA, Magnussen H. Effect of Fluticasone Propionate on the airway response to hypertonic saline in patientes with COPD. Am J Respir Crit Care Med 2004; 169: A596
  1. Taube C, Kanniess F, Grönke L, Richter K, Mücke M, Paasch K, Eichler G, Jörres RA, Magnussen H. Reproducebility of forced inspiratory and expiratory volumes after bronchodilation in COPD and asthma. Respir Med. 2003; 97: 568 -577.
  2. Zuhlke IE, Kanniess F, Richter K, Nielsen-Gode D, Bohme S, Jorres RA, Magnussen H. Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. Eur Respir J 2003;22:926-30
  3. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Eur Respir J 2003; 22: 470-477
  1. Grönke L, Kanniess F, Holz O, Jörres RA, Magnussen H. The relationship between airway inflammation and hyperresponsiveness depends on the duration of the asthmatic disease Clin Exp Allergy. 2002; 32: 57 - 63.
  2. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Montelukast vs. Fluticasone: Effects on lung function, airway responsiveness and markers of inflammation in moderate asthma Eur Respir J 2002; 20: 853 - 858
  3. Kanniess F, Richter K, Janicki S, Schleiss MB, Jörres RA, Magnussen H. Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. Eur Respir J 2002; 20: 1080 - 1087
  1. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharm Ther 2001; 14: 141 - 147
  2. Kanniess F, Jörres RA, Magnussen H. Combined inhalation of nitric oxide and oxygen in patients with moderate to severe COPD: effect on blood gases Respiratory Medicine 2001; 95: 927 - 934
  3. Loppow D, Schleiss M, Kanniess F, Taube C, Jörres RA, Magnussen H In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respiratory Medicine 2001; 95: 115 - 121
  1. Kanniess F, Magnussen H: Problemfall Asthma Bronchiale Atemwegs- und Lungenerkrankungen 2000
  1. Kanniess F., Magnussen H Evolution and impact of international and national guidelines. Respiratory Care Matters 1999
  2. Magnussen H, Kanniess F. Diagnostik des Asthma bronchiale Internist 1999; 40: 830 - 836
  3. Magnussen H., Kanniess F., Richter K: Difficult or therapy resistant asthma: clinical phenotypes of near fatal, fatal, premenstrual and chronic fixed asthma Eur Respir Rev 2000; 10: 69, 5-10
  1. Kanniess F, Behnke M, Lehnigk B, Hansen J, Jessat H, Jörres RA, Magnussen H. Combined inhalation of nitric oxide and oxygen in patients with severe COPD: effects on PaO2. Eur Respir J 1998; 12: 353s(Abstrakt)
  2. Kanniess F. Im Fokus: Brittle Asthma. Pneumologie 1998; 52: 543-544
  3. Richter K, Kanniess F., Marck B., Jörres RA., Magnussen H.: Assessment of accuracy and applicabilty of a new electronic peak-flow meter and asthma monitor. Eur Respir J 1998 12: 457-462